In this report, we present an update of the 2020 primary systematic review, to take into account more recent evidence on the efficacy, effectiveness and safety of newer and/or enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over.
The annual influenza meeting focused on new developments in influenza surveillance at the country and regional level, seasonal influenza vaccination programmes, provided an update on the global situation with regard to outbreaks of avian influenza and other emerging respiratory pathogens, and provided a forum for exchanging experiences from the past influenza season.
Antiviral drugs are an important addition to the public health arsenal against influenza. This interim guidance discusses the options for their effective use, especially during a pandemic.
Influenza is a disease of public health importance due to the substantial seasonal morbidity and mortality and the high pandemic potential of its aetiologic agents, influenza viruses.
This paper identifies and describes population groups at increased risk for severe outcomes of influenza (“risk groups”) and advocates vaccination for two major groups, namely a) persons in the older age group, usually 65 years and older; and b) persons with chronic medical conditions.
Influenza is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and sometimes the lungs. It can cause mild to severe illness, and at times can lead to death. The best way to prevent flu is by getting a flu vaccine each year.